

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 872 547 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
21.10.1998 Bulletin 1998/43

(21) Application number: 95930006.2

(22) Date of filing: 30.08.1995

(51) Int. Cl.⁶: C12N 1/21, C12N 1/20,
C12P 13/08, C12P 13/06
// (C12N1/21, C12R1:19),
(C12P13/08, C12R1:19)

(86) International application number:
PCT/JP95/01719

(87) International publication number:
WO 96/06926 (07.03.1996 Gazette 1996/11)

(84) Designated Contracting States:
DE FR GB IT

(30) Priority: 30.08.1994 JP 204856/94

(71) Applicant: Ajinomoto Co., Inc.
Tokyo 104 (JP)

(72) Inventors:
• TOMITA, Fusao
Hokkaido 063 (JP)
• YOKOTA, Atsushi
Sapporo-shi Hokkaido 063 (JP)


• HASHIGUCHI, Kenichi
Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi Kanagawa 210 (JP)
• ISHIGOOKA, Masako
Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi Kanagawa 210 (JP)
• KURAHASHI, Osamu
Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi Kanagawa 210 (JP)

(74) Representative:
Strehl Schübel-Hopf & Partner
Maximilianstrasse 54
80538 München (DE)

(54) PROCESS FOR PRODUCING L-VALINE AND L-LEUCINE

(57) L-valine is produced by culturing a microorganism belonging to the genus *Escherichia* with the capability of producing L-valine or L-leucine wherein it requires lipoic acid for growth, a microorganism belonging to the genus *Escherichia* with the capability of producing L-valine or L-leucine wherein it is deficient in H⁺-ATPase activity, a microorganism belonging to the genus *Escherichia* with the capability of producing L-valine or L-leucine wherein it requires lipoic acid for growth and is deficient in H⁺-ATPase activity, in the liquid medium to allow the L-valine to be produced and accumulated in a culture medium, and collecting it.

FIG. 5



EP 0 872 547 A1

Descripti n

Technical Field

5 This invention relates to a microorganism belonging to the genus Escherichia having the capability of producing L-valine or L-leucine and, more particularly, a microorganism whose capability of producing L-valine or L-leucine is enhanced.

Background Art

10 In the past, L-valine and L-leucine have been produced by a method of fermentation primarily using a microorganism belonging to the genus Brevibacterium, Corynebacterium or Serratia or a mutant thereof which produces L-valine or L-leucine (Amino acid fermentation, JAPAN SCIENTIFIC SOCIETY'S PRESS, pp.397-422, 1986). Although the conventional methods have considerably enhanced the productivity of these amino acids, the development of a more efficient, cost-effective technique is required in order to meet increasing demand for L-valine and L-leucine in the future.

15 On the other hand, a microorganism belonging to the genus Escherichia is potentially utilized as a potent L-valine or L-leucine-producing microorganism due to its rapid growth rate, progress in genetic analysis and plentiful genetic materials. However, there are few reports documenting the production of these amino acids with from Escherichia microorganisms, and as for L-branched chain amino acids, only a few reports deal with the production of L-isoleucine (Japanese Patent Application Laid-Open No. 5-304969(1993) and Japanese Patent Application Laid-Open No. 5-130882(1993)).

Disclosure of the Invention

25 The object of the present invention, in view of the aforementioned points, is to provide an efficient and cost-effective method for producing L-valine and L-leucine by enhancing the capability of producing L-valine or L-leucine of a microorganism belonging to the genus

Escherichia.

30 As a result of a wholeheartedly conducted study of the production of L-valine and L-leucine by mutants of microorganisms belonging to the genus Escherichia, the present inventors have found that a mutation, whereby lipoic acid is required for growth and/or H⁺-ATPase is deficient, enhances the capability of producing L-valine or L-leucine of a L-valine or L-leucine-producing microorganism.

35 Thus, a first microorganism of the present invention is a microorganism belonging to the genus Escherichia and having the capability of producing L-valine or L-leucine, which requires lipoic acid for growth. A second microorganism of the present invention is a microorganism belonging to the genus Escherichia and having the capability of producing L-valine or L-leucine, which is deficient in H⁺-ATPase. Furthermore, a third microorganism of the present invention is a microorganism belonging to the genus Escherichia and having the capability of producing L-valine or L-leucine, which requires lipoic acid for growth and is deficient in H⁺-ATPase.

The present invention also provides a method for producing L-valine or L-leucine comprising culturing the aforementioned microorganism in a liquid medium to allow the L-valine or L-leucine to be produced and accumulated in the medium and collecting it.

45 In the specification, the phrase "H⁺-ATPase deficient" means that cells do not substantially express H⁺-ATPase activity, and includes both of that an H⁺-ATPase gene does not express due to entire or partial deletion of an atp operon coding for eight subunits of H⁺-ATPase or split of the atp operon and that the H⁺-ATPase gene has substitution, insertion or deletion of one or more nucleotides therein so that the H⁺-ATPase protein which is produced by expression of the gene does not have H⁺-ATPase activity. The ilvGMDA operon means a operon including each of ilvG, ilvM, ilvE and ilvD genes, and the operon may additionally include ilvA gene, which expresses inactivated threonine deaminase, or may not include ilvA gene substantially.

50 The invention will be described in detail as follows:

(1) Microorganism of the Present Invention

55 A microorganism of the invention is one which belongs to the genus Escherichia and has the capability of producing L-valine or L-leucine and has any one of the following properties:

1. Lipoic acid is required for growth.

2. H⁺-ATPase is deficient.

3. Lipoic acid is required for growth and H⁺-ATPase activity is deficient.

In the present invention, the microorganism may possess any one of the aforementioned properties 1 to 3, and preferably possess property 3.

A microorganism having such properties can be obtained by giving the capability of producing L-valine or L-leucine to a microorganism belonging to the genus Escherichia, which is mutated so that it requires lipoic acid for growth and/or is deficient in H⁺-ATPase, or by enhancing the capability of producing L-valine or L-leucine in the aforementioned mutant. The microorganism of the present invention can be also obtained by inducing a mutation whereby lipoic acid is required for growth and/or a mutation whereby H⁺-ATPase is deficient in a microorganism belonging to the genus Escherichia.

The microorganism to be used in obtaining the aforementioned microorganisms can include a strain, which belongs to the genus Escherichia such as Escherichia coli (hereinafter, also referred to as E. coli) and exhibits no pathogenicity. For example, the following strains can be used.

Escherichia coli K-12 (ATCC10798)
Escherichia coli W3110 (ATCC27325)
Escherichia coli W1485 (ATCC12435)

In order to introduce a mutation whereby lipoic acid is required for growth and/or a mutation whereby H⁺-ATPase is deficient into these microorganisms belonging to the genus Escherichia, the usual methods for introducing mutation, such as irradiation with X-ray or ultraviolet rays, or contact with mutagens including N-methyl-N'-nitro-N-nitrosoguanidine (hereinafter abbreviated as NG) and nitrous acid, can be applied. Additionally, the introduction of a mutation into a microorganism belonging to the genus Escherichia can be carried out by other genetic technique such as gene recombination, transduction, cell fusion and the like.

An example of the means for obtaining a mutant is as follows:

A mutant which requires lipoic acid for growth (hereinafter, referred to as a lipoic-acid-requiring strain) is obtained by culturing mutagenized bacterial cells on an agar plate, and by isolating colonies which exhibit lipoic acid requirement (A.A. Herbert and J.R. Guest: J. Gen. Microbiol., 53, 363-381 (1968)). As a lipoic acid requiring strain, specifically, E. coli W1485lip2 (ATCC25645) can be used.

A mutant which is deficient in H⁺-ATPase (hereinafter, referred to as a H⁺-ATPase-deficient strain) is obtained by selecting mutants which cannot grow on an agar plate containing citric acid as the sole carbon source and can grow on an agar plate containing glucose as the sole carbon source from mutagenized bacterial cells, and by further selecting, from these mutants, strains which do not exhibit H⁺-ATPase activity. As a H⁺-ATPase-deficient strain, specifically, E. coli AN718 (E. coli Genetic Stock Center, Yale University, Department of Biology) can be used.

H⁺-ATPase is a membrane-binding enzyme with approximately 500,000 KD in molecular weight, in which 8 types of subunits complicatedly associate, and functions to pump H⁺ outside of cytoplasm through changes in the free energy caused by ATP hydrolyzation and to synthesize ATP utilizing a H⁺-concentration gradient between the inside and outside of cytoplasmic membrane caused by intracellular respiration. Additionally, this enzyme is divided into an F0 fraction, which is localized on the inner membrane and exhibits H⁺-transport activity, and an F1 fraction, which is localized in the membrane surface and catalyzes the decomposition and synthesis of ATP, and the F0 is composed of 3 types of subunits a, b and c, while the F1 is composed of 5 types of subunits α , β , γ , δ , ϵ . A strain which has a mutation in any of these subunits can be used as a H⁺-ATPase-deficient strain. The mutation of the H⁺-ATPase deficiency may include the expression of a mutant subunit, and the non-expression of subunits comprising H⁺-ATPase by the mutation at a promoter site.

Further, because oxidative phosphorylation is not carried out in a H⁺-ATPase-deficient strain and energy is obtained by substrate-level phosphorylation, it is expected that the addition of various agents including H⁺-ATPase inhibitors, TCA cycle inhibitors, respiratory chain inhibitors and uncoupling agents to the culture medium results in the same effect as H⁺-ATPase deficiency. Such H⁺-ATPase inhibitors include dicyclohexylcarbodiimide, tributyltin, and aurovertin, TCA cycle inhibitors include malonic acid, moniodoacetic acid, methyl violet and 2,4-dinitrophenol, electron transport inhibitors include thenoyltrifluoroacetone, 2-n-nonyl-4-hydroxyquinoline-N-oxide and antimycin, and uncoupling agents include valinomycin, atebirin and 4,5,6,7-tetrafluoro-2-trifluoromethylbenzimidazol. These inhibitors may be used either alone or as a mixture of more than two types of inhibitors.

The lipoic-acid-requiring strain obtained as above is additionally mutagenized as a parent strain for selecting an H⁺-ATPase-deficient strain, or the H⁺-ATPase-deficient strain is additionally mutagenized as a parent strain for selecting a strain which comes to require lipoic acid, whereby a mutant which exhibits both lipoic acid requirement and H⁺-ATPase deficiency (hereinafter referred to as lipoic acid-requiring-H⁺-ATPase-deficient strain) can be obtained. Further, the mutant which exhibits both lipoic acid requirement and H⁺-ATPase deficiency can be obtained by introducing one of

these mutations in a mutant which exhibits the other mutation by transduction, transformation, cell fusion and the like.

For example, lipoic acid-requiring-H⁺-ATPase deficient strain can be obtained by transducing H⁺-ATPase deficiency into a lipoic acid-requiring strain as a parent strain. In this case, the aforementioned W1485lip2 strain can be used as a parent strain, and the aforementioned AN718 strain can be used as a donor strain. The lipoic acid-requiring-H⁺-ATPase-deficient strain can be obtained by transducing a lipoic acid requirement into a H⁺-ATPase-deficient strain as a parent strain.

The lipoic acid-requiring-H⁺-ATPase-deficient strain can include *E. coli* AJ12631. The strain AJ12631 has been deposited on July 24, 1991 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology under an accession number of FERM P-12381, transferred to international deposition based on the Budapest Treaty on August 29, 1995, and deposited under an accession number of FERM BP-5209.

A microorganism of the present invention can be obtained by giving the capability of producing L-valine or L-leucine to a lipoic acid requiring mutant, a H⁺-ATPase-deficient mutant or a lipoic acid-requiring-H⁺-ATPase-deficient mutant belonging to the genus *Escherichia*, or by enhancing the capability of producing L-valine or L-leucine in the aforementioned mutants. Additionally, the microorganism of the present invention can be also obtained by introducing a lipoic acid requirement and/or H⁺-ATPase deficiency in a microorganism belonging to the genus *Escherichia* having the capability of producing L-valine or L-leucine. Further, even for a microorganism being low in the capability of producing L-valine or L-leucine, this capability can be enhanced by introducing a lipoic acid requirement and/or H⁺-ATPase deficiency.

(1) L-valine-producing microorganism

An L-valine-producing microorganism can be obtained by giving the capability of producing L-valine to a lipoic acid-requiring mutant, a H⁺-ATPase-deficient mutant, or a lipoic acid-requiring-H⁺-ATPase-deficient mutant of a microorganism belonging to the genus *Escherichia*, or by enhancing the capability of producing L-valine in the aforementioned mutant.

The giving or enhancing of the capability of producing L-valine is carried out, for example, by introducing genes for L-valine biosynthesis, whose regulatory mechanism is substantially released, into a microorganism belonging to the genus *Escherichia*. A mutation which leads to the suppression of the regulatory mechanism of the genes for the L-valine biosynthesis of the microorganism belonging to the genus *Escherichia*, may be introduced.

In a microorganism belonging to the genus *Escherichia*, the final step of L-valine biosynthesis is carried out by a group of *ilvGMEDA* operon-encoded enzymes. The *ilvGMEDA* operon includes each of *ilvG*, *ilvM*, *ilvE*, *ilvD* and *ilvA* genes, which encodes a large subunit and a small subunit of isozyme II of acetohydroxy-acid synthase, transaminase, dihydroxy-acid dehydratase and threonine deaminase, respectively. Of these enzymes, acetohydroxy-acid synthase, transaminase and dihydroxy-acid dehydratase catalyze the synthetic pathways from pyruvic acid to L-valine and from 2-ketobutyric acid to L-isoleucine, and threonine deaminase catalyzes the deamination from L-threonine to 2-ketobutyric acid, which is a rate-limiting step of L-isoleucine biosynthesis. Therefore, to conduct the reaction of L-valine synthesis so that it proceeds efficiently, an operon which does not express active threonine deaminase is used preferably. As such *ilvGMEDA* operons, an *ilvGMEDA* operon in which a mutation leading to the production of an inactivated threonine deaminase is introduced to *ilvA* or *ilvA* is destroyed, or an *ilvGMED* operon in which *ilvA* is deleted, can be used.

Because of the regulation of the expression (attenuation) of an *ilvGMEDA* operon by L-valine and/or L-isoleucine and/or L-leucine, the region necessary for the attenuation is preferably deleted or mutated to release the regulation of the expression caused by the generating L-valine.

The aforementioned *ilvGMEDA* operon, which does not express threonine deaminase activity and whose attenuation is released, can be obtained by mutating a wild-type *ilvGMEDA* operon or modifying it with genetic recombination techniques.

The *ilvGMEDA* operon can include an operon derived from a microorganism belonging to the genus *Escherichia*, and particularly an *ilvGMEDA* operon derived from *E. coli*. Among microorganisms belonging to the genus *Escherichia*, the microorganism to be used is not particularly limited, however specifically, microorganisms described by Neidhardt, F.C. et al. (*Escherichia coli* and *Salmonella typhimurium*, American Society for Microbiology, Washington D.C., 1208, Table 1) can be utilized. When a wild-type strain is used as the donor strain of DNA including an *ilvGMEDA* operon, DNA including a wild-type *ilvGMEDA* operon is obtained.

However, when *E. coli* is used as the DNA donor strain of a wild-type *ilvGMEDA* operon, a wild-type K-12 strain does not express active isozyme II of acetohydroxy acid synthase (AHASII) because an *ilvG* gene possesses a frameshift mutation (Proc. Natl. Acad. Sci. USA, 78, 922, 1991). Therefore, when the K-12 strain is used as the DNA donor strain, it is necessary that a mutant, in which the frame is restored so as to recover the activity of the *ilvG* gene-encoded acetohydroxy-acid synthase, is prepared, and then used as the DNA donor strain. Otherwise, by using *E. coli*, other than a strain derived from the K-12 strain, as a DNA donor, only the *ilvG* gene may be isolated and introduced in *ilvGMEDA* operon derived from the K-12 strain. Thus, the *ilvMEDA* region is isolated from the K-12 strain as a DNA

donor, only the *ilvG* gene is isolated from *E. coli*, other than a strain derived from the K-12 strain, as a DNA donor, and the obtained both sequences are ligated together to form the full-length *ilvGMEDA* operon. The isozyme II of acetohydroxy-acid synthase (AHASII) is composed of two different large and small subunits. The large subunit is encoded by a *ilvG* gene. The small subunit is encoded by a *ilvM* gene.

The method of obtaining the *ilvGMEDA* operon which is released from the attenuation may be as follows:

The localization and DNA sequences of the attenuator which is 5'-upstream in the *ilvGMEDA* operon have been reported by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)).

Starting from *ilvGMEDA* which does not express active threonine deaminase, an *ilvGMEDA* operon wherein active threonine deaminase is not expressed and attenuator is deleted is obtained by preparing an *ilvGMEDA* operon wherein the attenuator is deleted.

The nucleotide sequence shown in SEQ ID NO:1 is a sequence including the promoter, the attenuator and the *ilvG* gene-coding region among nucleotide sequences of the *ilvGMEDA* operon and includes a region necessary for attenuation. An amino acid sequence coded by the *ilvG* gene is shown in SEQ ID NO:2. Nucleotides 966 to 971 of the DNA sequence encode two consecutive leucine residues localized in the leader peptide, nucleotides 999 to 1007 of the DNA sequence encode three consecutive valine residues localized in the leader peptide, and nucleotides 1008 to 1016 of the DNA sequence encode three consecutive isoleucine residues localized in the leader peptide. Nucleotides 1081 to 1104 of the DNA sequence encode a portion forming a rho-independent terminator-like stem-loop structure in the attenuator.

Sufficient amounts of L-isoleucine, L-valine and L-leucine in a cell lead to the formation of the rho-independent terminator-like stem-loop structure with the RNA which is a transcript encoded by nucleotides 1081 to 1104 of the DNA sequence so that RNA polymerase terminates transcription, which represses the expression of the *ilvGMEDA* operon.

For example, the shortage of L-valine in a cell results in the shortage of L-valine-binding tRNA, which causes ribosomal translation to be retarded at consecutive valine residues localized in the region encoding the leader peptide. This leads to the formation of an additional mRNA configuration in the three-dimensional structure, resulting in the formation of rho-independent terminator-like stem-loop structure in the RNA, which is stimulated by the transcription of nucleotides 1081 to 1104 the DNA sequence, is repressed. Thus, RNA polymerase continues transcription, which results in the expression of the *ilvGMEDA* operon. Similarly, the shortage of L-isoleucine or L-leucine leads to the expression of *ilvGMEDA* operon.

Therefore, to delete the region necessary for attenuation by L-valine, nucleotides 999 to 1007 or 1081 to 1104 of the DNA sequence shown in SEQ ID NO:1 may be deleted. Similarly, to delete the region necessary for attenuation by L-leucine in the production of L-leucine-producing microorganism as described below, nucleotides 966 to 971 or 1081 to 1104 of the DNA sequence disclosed in SEQ ID NO:1 may be deleted.

The deletion of the region necessary for attenuation means that the introduced mutation releases the attenuation. Therefore, this mutation is not limited to only the deletion of all attenuators which are upstream in the *ilvGMEDA* operon. Thus, the mutation may cause the attenuator not to form a rho-independent terminator-like stem-loop structure. Additionally, in the production of L-valine producing microorganism, the mutation may cause the leader peptide not to contain consecutive valine residues. Furthermore, in the production of L-leucine-producing microorganism, the mutation may cause the leader peptide not to contain consecutive leucine residues. Attenuation does not function in any of the aforementioned cases.

Thus, concepts of this deletion of the region necessary for attenuation include the insertion of an additional DNA fragment into the attenuator as well as the deletion of all parts or vicinities of attenuators which are 5'-upstream in the *ilvGMEDA* operon.

(i) Isolation of wild-type *ilvGMEDA* operon

To isolate a DNA containing the *ilvGMEDA* operon, the method, wherein *ilvGM*, *ilvE*, *ilvD* and *ilvA* genes are each isolated and then ligated, may be suggested. However, in the construction of an L-valine-producing microorganism, an *ilvA* gene encoding threonine deaminase is not necessary, so that *ilvGM*, *ilvE* and *ilvD* genes may be ligated to obtain a DNA including the *ilvGMED*.

First, *E. coli*, e.g. *E. coli* K-12, *E. coli* W3110, *E. coli* MC1061 (all of which include a frameshifted *ilvG*), *E. coli* MI162 (*thr-10*, *car-94*, λ^- , *relA1*, *ilvG603*, *thi-1*) or *E. coli* B (the latter two of which include a normal *ilvG*), is cultured to obtain the cultured cells. The microorganism may be cultured by the usual solid medium method, and preferably cultured according to the liquid medium method in consideration of efficiency in cell harvesting. A medium wherein yeast extracts, pepton, trypton or meat extracts are added to sodium chloride (NaCl) is to be used. Specifically, L-broth (Bacto-trypton 1%, Bacto-yeast extracts 0.5%, NaCl 0.5%, glucose 0.1%, pH 7.2) is to be used. The initial pH of the medium is preferably adjusted to 6-8. The cultivation is conducted at 30 to 42°C, preferably about 37°C, for 4-24 hours, with aeration, stirring and submerged in culture, with a shaking culture, or with a stationary culture. *E. coli* MI162 is available from the *E. coli* Genetic Stock Center (Connecticut, U.S.A.). The ID No. of this strain is CGSC5919. The detail

characteristics of this strain are described in Mol. Gen. Genet., 143, 243 (1976), and J. Bacteriol., 149, 294 (1982).

Thus, the obtained culture is centrifuged, e.g. at 3,000 r.p.m. for 5 minutes to obtain a pellet of *E. coli*. From this pellet, chromosomal DNA can be obtained by the method of Saitoh and Miura (Biochem. Biophys. Acta., 72, 619 (1963)) or K. S. Kirby (Biochem. J., 64, 405 (1956)).

To isolate the *ilvGMEDA* operon from the resulting chromosomal DNA, the chromosomal DNA library is prepared. First, the chromosomal DNA is partially digested by a proper restriction enzyme to obtain a mixture of different DNA fragments. A wide variety of restriction enzymes can be used if the digestion reaction is adjusted for the degree of digestion. For example, the chromosomal DNA is digested with *Sau3AI* at not less than 30°C, preferably at 37°C, at an enzyme concentration of 1-10 units/ml for a varying period of time (1 minute to 2 hours).

Subsequently, the digested DNA was ligated to vector DNA which allows autonomous replication to prepare recombinant DNA. Specifically, the vector DNA is completely digested and cleaved with the restriction enzyme, e.g. *BamHI*, which generates the restriction termini identical to those generated by *Sau3AI* used in the digestion of the chromosomal DNA, at a temperature of above 30°C, at a enzyme concentration of 1-100 units/ml for above 1 hour, preferably 1-3 hours. And then, the chromosomal DNA fragments and the cleaved vector DNA, obtained as mentioned above, were mixed, added to DNA ligase, preferably T4 DNA ligase, and reacted at a temperature of 4-16°C, at a enzyme concentration of 1-100 units/ml above 1 hour, preferably 6-24 hours to obtain recombinant DNA.

Using the resulting recombinant DNA, a microorganism belonging to the genus *Escherichia*, for example, a mutant which is deficient in acetohydroxy acid synthase activity such as *E. coli* M1262 (*leuB6*, *ilvI614*, *ilvH612*, Δ^- , *relA1*, *spoT1*, *ilvB619*, *ilvG603*, *ilvG605(am)*, *thi-1*), transaminase B-deficient mutants such as *E. coli* AB2070 (*proA2*, *trp-3*, *higG4*, *ilvE12*, *metE12*, *metE46*, *thi-1*, *ara-9*, *lac-Y1* or *lacZ4*, *galK2*, *malA1*, *mtl-1*, *rpsL8* or *rpsL9*, *ton-1*, *tsx-3*, Δ^B , Δ^- , *supE44*), or dihydroxy acid dehydratase-deficient mutants such as *E. coli* AB1280 (*hisG1*, *ilvD16*, *metB1*, *argH1*, *thi-1*, *ara-13*, *lacY1* or *lacZ4*, *gal-6*, *xyI-7*, *mtl-2*, *malA1*, *repsL8*, *9*, or *17*, *tonA2*, Δ^B , Δ^- , *supE44*), is transformed to prepare chromosomal DNA library. This transformation can be performed by the method of D.M. Morrison (Methods in Enzymology 68, 326, 1979) or a method wherein the treatment of a recipient cell with calcium chloride increases the permeability of DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)). *E. coli* M1262 is available from the *E. coli* Genetic Stock Center (Connecticut, U.S.A.). The ID No. of this strain is CGSC5769. The detailed characteristics of this strain are described in Mol. Gen. Genet., 156, 1 (1977). *E. coli* AB2070 is available from the *E. coli* Genetic Stock Center (Connecticut, U.S.A.). The ID No. of this strain is CGSC2070. The detailed characteristics of this strain are described in J. Bacteriol., 109, 730 (1972).

Because the nucleotide sequence of the full-length *ilvGMEDA* operon has been reported (Nucleic Acids Res., 15, 2137 (1987)), a certain length of DNA fragments including the aimed gene can be prepared by digesting the chromosomal DNA with a specific restriction enzyme. Only DNA fragments of a certain length are ligated to the vector DNA to generate recombinant DNA and to prepare the chromosomal DNA library, whereby the DNA fragment including the aimed gene can be obtained more efficiently.

From the obtained chromosomal DNA library, the strain which has recombinant DNA including the *ilvGM* gene is obtained by selecting a strain having increased acetohydroxy acid synthase activity or a strain whose nutrient requirement caused by the deficient in acetohydroxy acid synthase gene is complemented.

From the obtained chromosomal DNA library, the strain which has recombinant DNA including an *ilvE* gene is obtained by selecting a strain having increased transaminase B activity or a strain whose nutrient requirement caused by the deficiency in the transaminase B gene is complemented.

From the obtained chromosome DNA library, the strain which has recombinant DNA including an *ilvD* gene is obtained by selecting a strain having increased dihydroxy acid dehydratase activity or a strain whose nutrient requirement caused by the deficiency in the dihydroxy acid dehydratase gene is complemented.

To examine whether candidates to have recombinant DNA including the *ilvGM* gene have recombinant DNA when *ilvGM* gene is cloned or not, increase of acetohydroxy acid synthase activity is confirmed by preparing a cell extract from the candidate and further preparing a crude enzyme solution from this extract. The assay of acetohydroxy acid synthase activity can be performed by the method of M.D. Felice et al. (Methods in Enzymology 166, 241).

Because the AHAS-deficient strain exhibits isoleucine, leucine and valine requirements, when the acetohydroxy acid synthase-deficient mutant is used as a host cell, DNA fragments including the *ilvGM* gene can be obtained by isolating a strain which can grow in a minimum medium without valine, and by collecting recombinant DNA from said strain.

Otherwise, DNA sequence containing the *ilvGM* gene has been reported by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)). Thus, the confirmation can be performed by isolating the recombinant DNA from the candidates, by sequencing and comparing it with that described in the report.

As described above, there is a mutation within the open reading frame of the *ilvG* gene of *E. coli* K-12. As a result, the generated frameshift and further the emergence of a termination codon cause translational termination. Thus, the termination codon emerges at a position of 982-984 downstream of the initiation codon ATG (at a position of 1-3) of the *ilvG* gene. Therefore, when the *ilvGM* gene obtained from the strain is used, the mutation region needs to back to the normal sequence by the site-directed mutagenesis method. For example, for the *ilvG* gene (*ilvG603*) of *Escherichia coli*

MI162, the frame is normalized by placing two base pairs of TG before the termination codon TGA at a position of 982-984. The other mutations are described in Fig.2 in J. Bacteriol., 149, 294 (1982).

The method for confirming whether candidates to have recombinant DNA including the *ilvE* gene have recombinant DNA wherein *ilvE* gene is cloned or not is as follows. Because the transaminase B-deficient mutant exhibits an isoleucine requirement, when the transaminase B-deficient mutant is used as a host cell, DNA fragments including the *ilvE* gene can be obtained by isolating a strain which can grow in a minimum medium without isoleucine, and by collecting recombinant DNA from said strain.

Otherwise, the DNA sequence including the *ilvE* gene has been reported by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)). Thus, the confirmation can be performed by isolating the recombinant DNA from the candidates, by sequencing and comparing it with that described in the report.

The method for confirming whether candidates to have recombinant DNA including the *ilvD* gene have recombinant DNA wherein *ilvD* gene is cloned or not is as follows. Because the dihydroxy acid dehydratase-deficient mutant exhibits an isoleucine, leucine and valine requirement, when the dihydroxy acid dehydratase-deficient mutant is used as a host cell, DNA fragments including the *ilvD* gene can be obtained by isolating a strain which can grow in a minimum medium without valine, and by collecting recombinant DNA from said strain.

Otherwise, the DNA sequence including the *ilvD* gene has been reported by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)). Thus, the confirmation can be performed by isolating the recombinant DNA from the candidates, by sequencing and comparing it with that described in the report.

From each of the aforementioned strains, recombinant DNA can be isolated e.g. by the methods of P. Guerry et al. (J. Bacteriol., 166, 1064 (1973)) and D.B. Clewell (J. Bacteriol., 110, 667 (1972)).

To obtain a full-length *ilvGMEDA* operon, a DNA fragment including the *ilvGM* gene, a DNA fragment including the *ilvE* gene, and a DNA fragment including the *ilvD* gene are ligated. In the ligation, the DNA sequence of the full-length *ilvGMEDA* described by R.P. Lawther (Nucleic Acids Res., 15, 2137 (1987)) can be used as a reference.

A wild-type *ilvGMEDA* operon may be obtained by preparing chromosomal DNA from a strain having the wild-type *ilvGMEDA* in its chromosome by the method of Saitoh and Miura, and by amplifying the *ilvGMEDA* operon by the polymerase chain reaction method (PCR; see White, T.J. et al.; Trends Genet., 5, 185 (1989)). As a DNA primer in amplification, those complementary to both 3'-ends of DNA double strands including all or a part of the region of *ilvGMEDA* operon are used. In the amplification of only a part of the region of the *ilvGMEDA* operon, DNA fragments including the entire region are screened by using said DNA fragment as a probe. In the amplification of the entire region of the *ilvGMEDA* operon, an agarose gel electrophoresis of a PCR solution which contains DNA fragments including the amplified *ilvGMEDA* operon followed by extraction of the aimed DNA fragments allows for the collection of DNA fragments including the *ilvGMEDA* operon. Because in this case, also, the *ilvA* gene is not essential to the construction of a L-valine-producing microorganism, only the *ilvGMED* may be amplified.

When preparing a DNA primer, the DNA sequence of the full-length *ilvGMEDA* operon described by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)) can be used as a reference.

Primer DNA can be synthesized in a commercially available DNA synthesizer (e.g. Applied Biosystems, DNA synthesizer model 380B) by the phosphoramidite method (Tetrahedron Letters, 22, 1859 (1981)). PCR can be performed in a commercially available PCR system (Perkin Elmer, DNA thermal cycler PJ2000), using Taq DNA polymerase (supplied by Takara Shuzo, Ltd.) according to the method indicated by suppliers.

The *ilvGMEDA* operon amplified by the PCR method is ligated to vector DNA, which allows autonomous replication, in the cell of the microorganism belonging to the genus *Escherichia* and induced into the cell of a microorganism belonging to the genus *Escherichia*, whereby the induction of a mutation into the *ilvA* gene and the deletion of the region necessary for attenuation are facilitated. The vector DNA, transformation method, and further confirmation of the *ilvGMEDA* operon are the same as described above.

When *E. coli* K-12, *E. coli* W3110 and *E. coli* MC1061 are used as the donor microorganism of the *ilvGMEDA* operon, because a frameshift mutation is present within the open reading frame of the *ilvG* gene, this mutation needs to be normalized by the site-directed mutagenesis method. When *E. coli* MI162 (*thr-10, car-94, λ⁻, relA1, ilvG603, thi-1*), and *E. coli* B are used as the donor microorganism of the *ilvGMEDA* operon, the *ilvG* gene can be used as it is.

(ii) Deletion of the region of *ilvGMEDA* operon necessary for attenuation

Concepts of the deletion of the region necessary for attenuation from *ilvGMEDA* include an insertion of an additional DNA fragment into the attenuator as well as a deletion of all of, a part of or an area surrounding the attenuator which is upstream in the *ilvGMEDA* operon. Herein, the "attenuator" means a DNA sequence which forms a rho-independent terminator-like stem-loop structure. For example, the sequence corresponds to nucleotides 1081 to 1104 of the DNA sequence shown in SEQ ID NO:1.

To delete the attenuator, DNA fragments upstream and downstream of the attenuator in the *ilvGMEDA* operon may be each prepared to ligate the both DNA fragments. For example, the DNA fragment upstream of the attenuator in the

ilvGMEDA operon can be prepared by cleaving a DNA fragment including the full length of the ilvGMEDA operon with a proper restriction enzyme. Otherwise, the DNA fragment upstream of the attenuator in the ilvGMEDA operon may be amplified by the PCR method. The primer DNA used in the PCR method may be chemically synthesized on the basis of the DNA sequences described by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)) and G. Coopola et al. (Gene, 97, 21 (1991)). Furthermore, the DNA fragment upstream of the attenuator in the ilvGMEDA operon may be chemically synthesized.

The method for preparing the DNA fragment downstream of the attenuator in the ilvGMEDA operon is similar to that above.

Starting from the ilvGMEDA operon, the ilvGMEDA operon wherein part or vicinity of the attenuator is deleted may be prepared. Because the location and DNA sequence of the attenuator have been reported by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)), DNA to be deleted is determined on the basis of the sequence.

The DNA to be deleted is preferably the DNA sequence which is necessary to form a rho-independent terminator-like stem-loop structure, and/or includes the region encoding consecutive valine residues which are upstream in the stem-loop structure. To delete a part of or an area around the attenuator, DNA fragments upstream and downstream of the attenuator in the ilvGMEDA operon may be each prepared to ligate both DNA fragments. For example, the DNA fragment upstream in the attenuator of the ilvGMEDA operon can be prepared by cleaving a DNA fragment including the full length of the ilvGMEDA operon with a proper restriction enzyme. Otherwise, the DNA fragment upstream of the DNA to be deleted in the ilvGMEDA operon may be amplified by the PCR method. The primer DNA used in the PCR method may be chemically synthesized on the basis of the DNA sequences described by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)) and G. Coopola et al. (Gene, 97, 21 (1991)). Furthermore, the DNA fragment upstream of the DNA to be deleted in the ilvGMEDA operon may be chemically synthesized.

The method for preparing the DNA fragment downstream of the DNA to be deleted in the ilvGMEDA operon is similar to that above.

Starting from the ilvGMEDA operon, an ilvGMEDA operon wherein an additional DNA fragment is inserted into the attenuator may be prepared. Because the location and DNA sequence of the attenuator have been reported by R.P. Lawther et al. or G. Coppola et al., the position of the insertion and the DNA sequence of an additional DNA fragment to be inserted are determined on the basis of the sequence.

The additional DNA fragment to be inserted is preferably inserted into the DNA sequence which is necessary to form a rho-independent terminator-like stem-loop structure, or into the DNA region encoding consecutive valine residues which is upstream of the stem-loop structure. As a result of the insertion, the attenuator can not form a rho-independent terminator-like stem-loop structure and so the attenuator is expected to lose its function.

The DNA sequence of the additional DNA fragment to be inserted is preferably designed not to form a rho-independent terminator-like stem-loop structure, and to cause the consecutive valine residues not to be present upstream of the rho-independent terminator-like stem-loop structure when inserted.

To insert an additional DNA fragment into the attenuator, the DNA fragment of the ilvGEMED operon which is upstream of the additional DNA fragment to be inserted, the DNA fragment of the ilvGEMED operon which is downstream of the additional DNA fragment to be inserted, and the additional DNA fragment to be inserted may be prepared to ligate these three DNA fragments. For example, the DNA fragment upstream of the additional DNA fragment in the ilvGMEDA operon can be prepared by cleaving a DNA fragment including the full length of the ilvGMEDA operon with a proper restriction enzyme. Otherwise, the DNA fragment of the ilvGMEDA operon which is upstream of the additional DNA fragment may be amplified by the PCR method. The primer DNA used in the PCR method may be chemically synthesized on the basis of the DNA sequences described by R.P. Lawther et al. (Nucleic Acids Res., 15, 2137 (1987)) and G. Coopola et al. (Gene, 97, 21 (1991)). Furthermore, the DNA fragment upstream of the additional DNA fragment in the ilvGMEDA operon may be chemically synthesized.

The method for preparing the DNA fragment downstream of the additional DNA fragment in the ilvGMEDA operon is similar to that above.

The additional DNA fragment to be inserted can be prepared by chemical synthesis.

In the amplification of the DNA fragment of the ilvGMEDA operon which is upstream of the DNA region into which the additional DNA fragment, or the DNA fragment of the ilvGMEDA operon which is downstream of the DNA region into which the additional DNA fragment, the additional DNA fragment to be inserted can be ligated with the primer DNA. For example, the 3'-end DNA primer used for the amplification of the DNA fragment upstream of the DNA region into which the additional DNA fragment is ligated with one of the strands of the additional DNA fragment to be inserted. Similarly, the 5'-end DNA primer used for the amplification of the DNA fragment downstream of the DNA region into which the additional DNA fragment is ligated with the complementary one of the strands of the additional DNA fragment to be inserted. Two different DNA fragments which have been amplified using above-mentioned primers are ligated.

(iii) Inactivation of threonine deaminase

When the obtained *ilv* operon contains an *ilvA* gene, the *ilvA* is deleted, or modified to cause a mutation, insertion and deletion within the *ilvA* so as to inactivate the expressed threonine deaminase. As a modification, for example, a restriction site in the *ilvA* gene can be cleaved to delete a DNA fragment which is downstream in the cleaved site. A DNA fragment may be cut out by cleaving the *ilvA* gene at two sites and then re-ligating it. Further, the expressed threonine deaminase can be inactivated by inserting another DNA fragment such as a synthesized DNA into the restriction site. When the restriction sites are cohesive ends, these cohesive ends are treated so as to be blunt ends, and then the resulting ends are ligated together, whereby the expressed threonine deaminase can be inactivated. Furthermore, the expressed threonine deaminase can be inactivated by site-specific mutagenesis and the like.

Hereinafter, the *ilvGMEDA* operon, wherein attenuation is repressed and the threonine deaminase activity is not expressed, or *ilvA* is deleted, is referred to as a derepressed *ilvGMEDA** operon, where A* represents the deleted *ilvA* gene, or the *ilvA* encoding inactivated threonine deaminase or a part thereof.

(iv) Introduction of derepressed *ilvGMEDA** operon in a microorganism belonging to the genus *Escherichia*

A DNA fragment including the derepressed *ilvGMEDA** operon obtained as above used as a recombinant DNA, introduced into a proper host microorganism and expressed, whereby the microorganism, in which the expression of the enzymes involving valine biosynthesis encoded by the *ilvGMEDA** operon is enhanced, can be obtained. As a host microorganism, a microorganism belonging to the genus *Escherichia*, e.g. *Escherichia coli*, is preferably used.

A derepressed *ilvGMEDA** operon, which is cut out from a recombinant DNA and inserted into the other vector DNA, may be used. As the vector DNA which can be used in the present invention, for example, pUC19, pUC18, BR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219 and pMW218 can be used. Additionally, a vector of phage DNA also can be used.

Further, to efficiently perform the expression of the derepressed *ilvGMEDA** operon, the other promoters, which act in a microorganism including *lac*, *trp* and *P_L*, may be ligated, and the promoter innate to the *ilvGMEDA** operon may be used as it is or after amplification.

As mentioned above, the DNA fragment including the derepressed *ilvGMEDA** operon may be present in a host microorganism as an extrachromosomal DNA such as a plasmid by inserting the operon into vector DNA which allows autonomous replication into the host, while the derepressed *ilvGMEDA** operon may be inserted into the chromosome of the host microorganism by using the techniques of transduction, a transposon (Berg, D.E. and Berg, C. M., Bio/Technology, 1, 417 (1983)), a Mu phage (Japanese Patent Application Laid-Open No. 2-109985(1990)) or by homologous recombination (Experiments in Molecular Genetics, Cold Spring Harbor Lab. (1972)). The number of the derepressed *ilvGMEDA** operons introduced into the host may be either one or more.

As described above, an L-valine producing microorganism can be obtained by introducing the DNA fragment including the derepressed *ilvGMEDA** operon into a lipoic acid requiring and/or H⁺-ATPase-deficient microorganism belonging to the genus *Escherichia*. Also, an L-valine-producing microorganism can be obtained by introducing lipoic acid requirement and/or H⁺-ATPase deficiency to a microorganism belonging to the genus *Escherichia* and carrying the DNA fragment including the derepressed *ilvGMEDA** operon.

(2) L-leucine-producing microorganism

As illustrated in the example below, it is found that a lipoic acid-requiring or H⁺-ATPase-deficient microorganism belonging to the genus *Escherichia* can increase the L-valine productivity. This finding suggests that a lipoic acid-requiring mutation or H⁺-ATPase-deficient mutation causes the intracellular metabolism to stimulate the L-valine synthesis. Therefore, the lipoic acid requiring mutation or H⁺-ATPase-deficient mutation is considered to promote L-leucine biosynthesis whose synthetic pathway branches out from the final intermediate of L-valine. Thus, if the capability of producing L-leucine is added to or enhanced in a lipoic acid-requiring mutant, a H⁺-ATPase-deficient mutant, or a lipoic acid-requiring and H⁺-ATPase-deficient mutant, the capability of producing L-leucine is expected to be added thereto or enhanced.

The addition or enhancement of the capability of producing L-leucine, for example, is performed by introducing an L-leucine biosynthetic gene, wherein the regulatory mechanism is substantially released, into a microorganism belonging to the genus *Escherichia*, in addition to the properties necessary for the production of L-valine. And a mutation, whereby the regulatory mechanism of L-leucine biosynthesis in a microorganism belonging to the genus *Escherichia* is substantially released, may be introduced. These genes can include, for example, a *leuA* gene in which inhibition by L-leucine is substantially released.

In addition to the aforementioned capability of producing L-valine or L-leucine, a microorganism of the present invention may have the known characteristics which are effective in enhancing its capability of producing an amino acid,

for example, various nutrient requirements, resistance to drugs, sensitivity to drugs, and drug dependence, or characteristics wherein a gene promoting the biosynthesis of an amino acid is amplified by means of gene engineering.

(2) Production of L-valine or L-leucine of the present invention

The production of L-valine or L-leucine of the invention can be performed by culturing the microorganism of the present invention in a liquid medium, to allow L-valine or L-leucine to be produced and accumulated in the liquid medium, and collecting L-valine or L-leucine from this liquid medium. In this production, the L-valine-producing microorganism of the present invention is used in the production of L-valine, and the L-leucine producing microorganism of the present invention is used in the production of L-leucine.

In the producing method of the present invention, the cultivation of the L-valine or L-leucine-producing microorganism, the collection and purification of L-valine or L-leucine from the liquid medium may be performed in a manner similar to the conventional fermentation method wherein an amino acid is produced using a microorganism. A medium used for culture may be either a synthetic medium or a natural medium, so long as the medium includes a carbon source and a nitrogen source and minerals and, if necessary, appropriate amounts of nutrients which the microorganism requires for growth. The carbon source may include various carbohydrates such as glucose and sucrose, and various organic acids. Depending on the mode of assimilation of the used microorganism, alcohol including ethanol and glycerol may be used. As the nitrogen source, various ammonium salts such as ammonia and ammonium sulfate, other nitrogen compounds such as amines, a natural nitrogen source such as peptone, soybean-hydrolysate and digested fermentative microorganism are used. As minerals, potassium monophosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, calcium carbonate, etc. are used.

The cultivation is performed preferably under aerobic conditions such as a shake culture, and an aeration and stirring culture, at a temperature of 20 to 40°C, preferably 30 to 38°C. The pH of the culture is usually between 5 and 9, preferably between 6.5 and 7.2. The pH of the culture can be adjusted with ammonia, calcium carbonate, various acids, various bases, and buffers. Usually, a 1 to 3-day cultivation leads to the accumulation of the target L-valine or L-leucine in the liquid medium.

After cultivation, solids such as cells can be removed from the liquid medium by centrifugation and membrane filtration, and then the target L-valine or L-leucine can be collected and purified by ion-exchange, concentration and crystallization methods.

Brief Description of the Drawings

- Figure 1 is a scheme of the construction of the plasmid pHSGSK.
- Figure 2 is a scheme of the construction of the plasmid pdGM1.
- Figure 3 is a scheme of the construction of the plasmid pMWGMA2.
- Figure 4 is a scheme of the construction of the plasmid pMWD5.
- Figure 5 is a scheme of the construction of the plasmid pMWdAR6.

Best Mode to Carrying Out the Invention

The invention is described with reference to the following example:

Example 1

Creation of L-valine-producing microorganism

(1) Construction of pMWdAR6 carrying the derepressed *ilvGMEDA** operon

The chromosomal DNA was extracted from *Escherichia coli* M1162. The chromosomal DNA was cleaved with restriction enzyme *Hind*III. The length of a *Hind*III-*Hind*III DNA fragment including *ilvGM* genes was found to be 4.8 kb. Therefore, the *Hind*III-*Hind*III DNA fragment with approximately 4.8 kb and the DNA fragment obtained by digestion of the plasmid vector pBR322 (purchased from Takara Shuzo, Co., Ltd.) with *Hind*III, were ligated.

The resulting DNA-ligated mixture was induced into *Escherichia coli* M1162 which is an acetohydroxy-acid synthase-deficient strain. The strains in which the deficiency of acetohydroxy-acid synthase was complemented by transformation were selected and the plasmid structure was isolated from the selected strains. The results of the analysis of the plasmid revealed that a 4.8-kb DNA fragment containing the *ilvGM* gene and a portion of 5'-terminal of *ilvE* gene was inserted into the *Hind*III site of the pBR322. The plasmid was termed pBRGM7.

The synthetic oligonucleotides shown in SEQ ID NO:3 and NO:4 were synthesized with reference to the DNA

sequence of the *ilvGM* gene described in Gene, 97, 21, (1991), Pro. Natl. Acad. Sci. U.S.A., 78, 922, (1981) and J. Bacteriol., 149, 294, (1982). DNA was amplified by the PCR method, using both synthesized DNAs as a primer and chromosomal DNA of MI162 strain as a template. The amplified DNA fragment included nucleotides 25 to 952 of the nucleotide sequence shown in SEQ ID NO:1. The fragment was termed Fragment (A).

Similarly, the synthetic oligonucleotides shown in SEQ ID NO:5 and NO:6 were synthesized with reference to the DNA sequence described in Gene, 97, 21, (1991), Pro. Natl. Acad. Sci. U.S.A., 78, 922, (1981) and J. Bacteriol., 149, 294, (1982). DNA was amplified by the PCR method, using both synthesized DNAs as a primer and chromosomal DNA of the MI162 strain as a template. The amplified DNA fragment included nucleotides 1161 to 2421 of the nucleotide sequence shown in SEQ ID NO:1. The fragment was termed Fragment (B).

The plasmid pUCA was prepared by ligating the large fragment obtained by digestion of Fragment (A) with *Sma*I and the DNA fragment obtained by digestion of the vector, pUC18 (Takara Shuzo, Co., Ltd.) with *Sma*I. The plasmid pHSGB was prepared by ligating the large fragment obtained by digestion of Fragment (B) with *Kpn*I and the DNA fragment obtained by digestion of the vector, pHS399 (Takara Shuzo, Co., Ltd.) with *Hinc*II and *Kpn*I.

The plasmid pUCA was digested with *Kpn*I, the blunt-end fragment was prepared with the large fragment of DNA polymerase I (Klenow fragment), and digested with *Pst*I, and finally, a DNA fragment containing Fragment (A) was isolated. Plasmid pHSGB was digested with *Hind*III, the blunt-end fragment was prepared with the large fragment of DNA polymerase I (Klenow fragment), and digested with *Pst*I, and finally, a DNA fragment containing Fragment (B) was isolated. The plasmid pHS399 was prepared by ligating both DNA fragments.

The *Sma*I-*Kpn*I fragment derived from Fragments (A) and (B) in pHS399 was termed Fragment (C). Fragment (C) corresponded to a fragment obtained by digestion of a 4.8-kb *Hind*III-*Hind*III fragment with *Sma*I and *Kpn*I contained a promoter, the SD sequence and an upstream region of the *ilvG* gene, but lost the DNA sequence of 0.2 kb from a leader sequence to an attenuator. The scheme of construction of pHS399 is summarized in Fig. 1.

Fragment (C) was obtained by digestion of the plasmid pHS399 with *Sma*I and *Kpn*I, the large DNA fragment was obtained by digestion of the plasmid pBRGM7 with *Sma*I and *Kpn*I, and the both two fragments were ligated. The obtained plasmid was termed pdGM1. pdGM1 harbored a 4.6-kb *Hind*III-*Hind*III fragment including the *ilvGM* gene, which lost the region necessary for attenuation. This *ilvGM* gene which loses the region necessary for attenuation represents "ΔattGM". The scheme of the construction of pdGM1 is summarized in Figure 2.

The plasmid pDRIA4 described in Japanese Patent Application Laid-Open No. 2-458(1990) is prepared by combining the shuttle vector pDR1120, which allows autonomous replication in both a microorganism belonging to the genus *Escherichia* and a microorganism belonging to the genus *Brevibacterium*, with a *Bam*HI-*Bam*HI fragment including the *ilvA* gene encoding threonine deaminase and a portion of the 3'-terminal of the *ilvD* gene derived from *E. coli* K-12. Japanese Patent Application Laid-Open No. 2-458(1990) describes that the length of the *Bam*HI-*Bam*HI fragment is 2.3 kb; however, at present, the length of this fragment has been found to be 2.75 kb. The plasmid pDRIA4 is not present within the chromosomal DNA of *Brevibacterium flavum* AJ12358 (FERM P-9764) or *Brevibacterium flavum* AJ12359 (FERM P-9765). From these strains, the plasmid pDRIA4 can be prepared according to the usual method. The feedback inhibition of threonine deaminase encoded by the *ilvA* gene in pDRIA4 by L-isoleucine is released, whereas this release of the feedback inhibition is not essential in the present invention.

From a 2.75-kb *Bam*HI-*Bam*HI DNA fragment in the plasmid pDRIA4, a *Hind*III-*Bam*HI fragment including the *ilvA* gene encoding threonine deaminase, in which the inhibition by L-isoleucine was released, was prepared, and ligated to a DNA fragment obtained by cleaving the vector pMW119 (NIPPON GENE) with *Hind*III and *Bam*HI. The resulting plasmid was termed pMWA1.

A DNA fragment obtained by cleaving the plasmid pMWA1 with *Hind*III and a DNA fragment obtained by cleaving the plasmid pdGM1 with *Hind*III were ligated. According to the analysis of the position of the restriction sites of the ligated plasmids, the plasmid in which the transcriptional orientations of the *ilvGM* and *ilvA* genes were the same was selected, and termed pMWGMA2. The pMWGMA2 includes the *ilvGM* gene in which an attenuator was deleted, a 5'-terminal portion of the *ilvE* gene, and a 3'-terminal portion of the *ilvD* gene. The scheme of the construction of pMWGMA2 is summarized in Figure 3.

The chromosomal DNA of *Escherichia coli* MI162 was prepared and cleaved with *Sal*I and *Pst*I to prepare the mixture of DNA fragments. On the other hand, a DNA fragment was prepared by cleaving the vector pUC19 (Takara Shuzo, Co., Ltd.) with *Sal*I and *Pst*I. The mixture of DNA fragments was ligated to the DNA fragment obtained by cleaving pUC19, and the DNA mixture was obtained. The DNA mixture was induced into AB2070, a transaminase B-deficient strain, (provided from *Escherichia coli* Genetics Stock Center. J. Bacteriol., 109, 703, (1972), CGSC2070) and a transformant, in which the branched-chain amino-acid requirement was recovered, was selected. As a result of the preparation of a plasmid from the strain, the plasmid harbored a DNA fragment obtained by cleaving the plasmid pUC19 with *Sal*I and *Pst*I, and a *Sal*I-*Pst*I DNA fragment including the *ilvE* gene, which were ligated. The plasmid was termed pUCE1. The pUCE1 includes a 3'-terminal portion of the *ilvM* gene, the *ilvE* gene, and a 5'-terminal portion of the *ilvD* gene.

A DNA-fragment mixture was prepared by partially digesting pMWGMA2 with *Hind*III. On the other hand, a 1.7-kb

HindIII-HindIII DNA fragment containing a portion of the ilvE gene and a 5'-terminal portion of the ilvD gene was prepared by cleaving pUCE1 with HindIII. Using a DNA mixture obtained by ligating both of the DNA fragments, AB1280, a dihydroxy-acid dehydratase(ilvD gene product)-deficient strain, was transformed, and the strain which recovered branched chain amino acid requirement was selected from the transformants. In the plasmid prepared from the resulting transformant, a DNA fragment obtained by cleaving only the HindIII site between $\Delta attGM$ and ilvA of pMWGMA2 with HindIII, and a 1.7-kb HindIII-HindIII DNA fragment including a portion of the ilvE gene and a portion of the ilvD gene derived from pUCE1 were ligated, and the ilvGMEDA operon was reconstructed. The plasmid was termed pMWD5. The scheme of the construction of pMWD5 is summarized in Figure 4.

The resulting plasmid pMWD5 derived from the vector pMW1 19 harbors the ilvGMEDA operon in which the region necessary for attenuation is deleted.

Subsequently, the plasmid pMWD5 was completely digested with SnaBI and then partially digested with AccIII. The resulting DNA fragment was self-ligated to obtain the plasmid pMWdAR6 in which only the ilvA gene was destroyed (Figure 5). This plasmid pMWdAR6 includes the ilvGMEDA operon in which the region necessary for attenuation is deleted and the ilvA gene is destroyed.

(2) Creation of L-valine-producing-microorganism

Using the plasmid pMWdAR6 carrying the ilvGMED operon which was obtained as described above, E. coli W1485lip2 (ATCC25645), a lipoic acid-requiring mutant; E. coli W1485atpA401, a H^+ -ATPase-deficient mutant; E. coli AJ12631 (FERM P-12381); a lipoic acid-requiring and H^+ -ATPase-deficient mutant, and wild-type E. coli W1485 (ATCC12435) were each transformed and the following transformants were obtained:

- 1) E. coli W1485/pMWdAR6
- 2) E. coli W1485atpA401/pMWdAR6
- 3) E. coli W1485lip2/pMWdAR6
- 4) E. coli AJ12631/pMWdAR6

E. coli AJ12631 was obtained by transducing atpA401, a mutant gene, encoding mutant alpha subunit of F1 of H^+ -ATPase derived from E. coli AN718 (CGSC6308) into E. coli W1485lip2 (ATCC25645) (see Japanese Patent Application Laid-Open No. 5-137568(1993)). In selection of a transduced strain with a H^+ -ATPase-deficient mutation, bgl gene positioned in the vicinity of atpA401 gene was used as a marker. Since the bgl gene encodes phospho-beta-glucosidase, E. coli having the wild-type bgl gene (bgl⁺) cannot assimilate salicin, whereas E. coli having the mutant bgl gene (bgl⁻) can grow utilizing salicin as the sole carbon source, so that the colonies of a salicin-assimilating strain make a bromothymol blue-added medium plate turn yellow by an organic acid produced by the strain. Therefore, if the mutant bgl gene (bgl⁻) and atpA401 gene are linked-transduced, a H^+ -ATPase-deficient mutant can be selected efficiently. First, the salicin-assimilating (bgl⁻) strain was isolated from E. coli AN718, and then AN718 (bgl⁻) was infected by Plkc, and E. coli W1485lip2 was transduced using the obtained lysate. For the resulting transductant, a lipoic acid requirement and H^+ -ATPase activity was determined to confirm the presence of lipoic acid-requiring and H^+ -ATPase-deficient mutations.

Similarly, E. coli W1485atpA401 was obtained by transducing atpA401 into E. coli W1485.

Example 2

Production of L-valine

The L-valine productivity of L-valine-producing microorganism obtained in Example 1 was evaluated. Each of transformants was plated on the medium comprising Bacto-typtone 1%, yeast extract 0.5%, NaCl 0.5%, agar 1.5%, and ampicillin 100 μ g/ml, cultured at 37°C for 18 to 24 hours, and then a part of them was transferred to 20 ml of a fermentation medium (glucose 4%, ammonium sulfate 1.6%, potassium dihydrogen-phosphate 0.1%, magnesium sulfate heptahydrate 0.1%, ferrous sulfate heptahydrate 0.001%, manganese sulfate pentahydrate 0.001%, yeast extract 0.2%, Bacto-tryptone 0.2%, calcium carbonate 3%, pH 7.0) with a platinum transfer loop, and incubated at 37°C for 24 hours. In culture of lipoic acid-requiring mutant, lipoic acid was added at a final concentration of 1 μ g/L.

The concentration of L-valine in the supernatant of the culture, from which the cells were removed, was determined by high-performance liquid chromatography using a cation exchange column (CPK08: Asahi Chemical Industry Co., Ltd.). The results are shown in Table 1.

Table 1

Productivity of the L-valine of each strain	
<u>E. coli</u> transformant	Productivity of L-valine (g/L)
W1485	0.1
W1485/pMWdAR6	6.9
W1485atpA401/pMWdAR6	8.0
W1485lip2/pMWdAR6	7.8
AJ12631/pMWdAR6	9.2

The results reveal that when a DNA fragment including the ilvDMEDA⁺ operon in which threonine deaminase activity is not expressed and the region necessary for attenuation is deleted is introduced into a lipoic acid-requiring and/or H⁺-ATPase-deficient E. coli as a host cell, the resulting E. coli showed enhanced productivity of L-valine. If a lipoic acid-requiring and H⁺-ATPase-deficient strain is used as a host, the productivity of L-valine can be further enhanced.

Industrial Applicability

According to the present invention, it becomes possible to enhance the capability of L-valine or L-leucine production of a L-valine or L-leucine-producing microorganism. By using a microorganism of the present invention, L-valine and L-leucine can be produced efficiently.

Sequence Listing

5

(1) GENERAL INFORMATION:

(i) APPLICANT: AJINOMOTO CO., LTD.

10

(ii) TITLE OF INVENTION: METHODS FOR PRODUCING L-VALINE AND L-LEUCINE

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: Ajinomoto Co., Ltd.

(B) STREET: 15-1, Kyobashi 1-chome, Chuo-ku

(C) CITY: Tokyo 104

(D) STATE:

(E) COUNTRY: Japan

20

(F) ZIP:

(v) COMPUTER READABLE FORM:

25

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: FastSEQ Version 1.5

(vi) CURRENT APPLICATION DATA:

30

(A) APPLICATION NUMBER:

(B) FILING DATE: 30.08.95

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

35

(A) NAME: Strehl Schübel-Hopf Groening & Partner

(B) REGISTRATION NUMBER: 94

(C) REFERENCE/DOCKET NUMBER: EPA-43613

40

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: [49](89)22 39 11

(B) TELEFAX: [49](89)22 39 15

45

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

50

(A) LENGTH: 2841 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

55

(ii) MOLECULAR TYPE: genomic DNA
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Escherichia coli

(B) STRAIN: M1162

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 957..1055

(C) IDENTIFICATION METHOD: S

(ix) FEATURE:

(A) NAME/KEY: attenuator

(B) LOCATION: 1081..1104

(C) IDENTIFICATION METHOD: S

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1195..2841

(C) IDENTIFICATION METHOD: S

(ix) FEATURE:

(A) NAME/KEY: cleavage-site(SmaI)

(B) LOCATION: 52..57

(C) IDENTIFICATION METHOD: S

(ix) FEATURE:

(A) NAME/KEY: cleavage-site(KpnI)

(B) LOCATION: 2395..2400

(C) IDENTIFICATION METHOD: S

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTCGCTTTCC TTGTTCTGA CCGATAACAT CACTGAGATC ATGTTGTAGC GCCCGGGATA	60
CTGCATCAGT TGGTTTCGGG CGTTCGAGAG CGTGCTTACC TTCCAGAAAC GCACAGACAG	120
CTTGCAGATG ATCGGCTATC AGGCATCCTT CACCGTTAAT TAGCCCCACT TCATCTTCGT	180
TATCTTTTCG CACGATAATT TTTCTGCCCG ACTTAATAGC TTCAGTTGCA CTGGAGATTG	240
CGCCGGGAAC GCCACGCAGA GCGCCTGTAA GCGCCAGTTC TCCGACTAAT TCATATTCAT	300
CTAACTTATT GGCTGTAAGC TGTTCGAGG CCGCCAGCAA CGCAATGGCG ATAGGTAAT	360
CATATCGTCC CCCTTCTTTT GGCAGATCAG CTGGAGCCAG GTTGATGGTG ATTTTTTTCG	420
CCGGATATTC ATATCCGCTA TTGATAATGG CGCTGCGCAC GCGATCGCGA GCTTCTTTTA	480

EP 0 872 547 A1

	CCGTTGTTTC TGGTAAGCCC ACCATCGTTA AGCCGGGTAG ACCTTTACTG ATATGTACCT	540
	CAACAGTGAT CGGGGGCGCA TTTACTCCCA GGGCTGCGCG GGTATGAACA ATTGACAGTG	600
5	ACATAAGCCC TCCTTGAGTC ACCATTATGT GCATAAGATA TCGCTGCTGT AGCCCGCTAA	660
	TTCGTGAATT TTAGTGGCTG ATTCCTGTTT ATTTGTGCAA GTGAAGTTGA GTTGTCTCG	720
	CGGTGGAATG ATGCTCGCAA AAATGCAGCG GACAAAGGAT GAACTACGAG GAAGGGAACA	780
10	ACATTCATAC TGAAATTGAA TTTTTTTCAC TCACTATTTT ATTTTAAAA AACAACAATT	840
	TATATTGAAA TTATTAAACG CATCATAAAA ATCGGCCAAA AAATATCTTG TACTATTAC	900
	AAAACCTATG GTAACCTTT AGGCATTCTT TCGAACAAGA TGCAAGAAAA GACAAA	956
15	ATG ACA GCC CTT CTA CGA GTG ATT AGC CTG GTC GTG ATT AGC GTG GTG	1004
	Met Thr Ala Leu Leu Arg Val Ile Ser Leu Val Val Ile Ser Val Val	
	1 5 10 15	
	GTG ATT ATT ATC CCA CCG TGC GGG GCT GCA CTT GGA CGA GGA AAG GCT	1052
20	Val Ile Ile Ile Pro Pro Cys Gly Ala Ala Leu Gly Arg Gly Lys Ala	
	20 25 30	
	TAGAGATCAA GCCTTAACGA ACTAAGACCC CCGCACCGAA AGGTCCGGGG GTTTTTTTTG	1112
25	ACCTTAAAAA CATAACCGAG GAGCAGACAA TGAATAACAG CACAAAATTC TGTCTCTCAA	1172
	GATTGAGGAC GGGGAACTAA CT ATG AAT GGC GCA CAG TGG GTG GTA CAT GCG	1224
	Met Asn Gly Ala Gln Trp Val Val His Ala	
	1 5 10	
30	TTG CGG GCA CAG GGT GTG AAC ACC GTT TTC GGT TAT CCG GGT GGC GCA	1272
	Leu Arg Ala Gln Gly Val Asn Thr Val Phe Gly Tyr Pro Gly Gly Ala	
	15 20 25	
35	ATT ATG CCG GTT TAC GAT GCA TTG TAT GAC GGC GGC GTG GAG CAC TTG	1320
	Ile Met Pro Val Tyr Asp Ala Leu Tyr Asp Gly Gly Val Glu His Leu	
	30 35 40	
40	CTA TGC CGA CAT GAG CAG GGT GCG GCA ATG GCG GCT ATC GGT TAT GCT	1368
	Leu Cys Arg His Glu Gln Gly Ala Ala Met Ala Ala Ile Gly Tyr Ala	
	45 50 55	
45	CGT GCT ACC GGC AAA ACT GGC GTA TGT ATC GCC ACG TCT GGT CCG GGC	1416
	Arg Ala Thr Gly Lys Thr Gly Val Cys Ile Ala Thr Ser Gly Pro Gly	
	60 65 70	
50	GCA ACC AAC CTG ATA ACC GGG CTT GCG GAC GCA CTG TTA GAT TCC ATC	1464
	Ala Thr Asn Leu Ile Thr Gly Leu Ala Asp Ala Leu Leu Asp Ser Ile	
	75 80 85 90	

55

EP 0 872 547 A1

	CCT GTT GTT GCC ATC ACC GGT CAA GTG TCC GCA CCG TTT ATC GGC ACT	1512
	Pro Val Val Ala Ile Thr Gly Gln Val Ser Ala Pro Phe Ile Gly Thr	
5	95 100 105	
	GAC GCA TTT CAG GAA GTG GAT GTC CTG GGA TTG TCG TTA GCC TGT ACC	1560
	Asp Ala Phe Gln Glu Val Asp Val Leu Gly Leu Ser Leu Ala Cys Thr	
10	110 115 120	
	AAG CAT AGC TTT CTG GTG CAG TCG CTG GAA GAG TTG CCG CGC ATC ATG	1608
	Lys His Ser Phe Leu Val Gln Ser Leu Glu Glu Leu Pro Arg Ile Met	
	125 130 135	
15	GCT GAA GCA TTC GAC GTT GCC TGC TCA GGT CGT CCT GGT CCG GTT CTG	1656
	Ala Glu Ala Phe Asp Val Ala Cys Ser Gly Arg Pro Gly Pro Val Leu	
	140 145 150	
20	GTC GAT ATC CCA AAA GAT ATC CAG TTA GCC AGC GGT GAC CTG GAA CCG	1704
	Val Asp Ile Pro Lys Asp Ile Gln Leu Ala Ser Gly Asp Leu Glu Pro	
	155 160 165 170	
	TGG TTC ACC ACC GTT GAA AAC GAA GTG ACT TTC CCA CAT GCC GAA GTT	1752
25	Trp Phe Thr Thr Val Glu Asn Glu Val Thr Phe Pro His Ala Glu Val	
	175 180 185	
	GAG CAA GCG CGC CAG ATG CTG GCA AAA GCG CAA AAA CCG ATG CTG TAC	1800
30	Glu Gln Ala Arg Gln Met Leu Ala Lys Ala Gln Lys Pro Met Leu Tyr	
	190 195 200	
	GTT GGC GGT GGC GTG GGT ATG GCG CAG GCA GTT CCG GCT TTG CGT GAA	1848
	Val Gly Gly Gly Val Gly Met Ala Gln Ala Val Pro Ala Leu Arg Glu	
35	205 210 215	
	TTT CTC GCT GCC ACA AAA ATG CCT GCC ACC TGT ACG CTG AAA GGG CTG	1896
	Phe Leu Ala Ala Thr Lys Met Pro Ala Thr Cys Thr Leu Lys Gly Leu	
	220 225 230	
40	GGC GCA GTA GAA GCA GAT TAT CCG TAC TAT CTG GGC ATG CTG GGG ATG	1944
	Gly Ala Val Glu Ala Asp Tyr Pro Tyr Tyr Leu Gly Met Leu Gly Met	
	235 240 245 250	
45	CAC GGC ACC AAA GCG GCA AAC TTC GCG GTG CAG GAG TGT GAC CTG CTG	1992
	His Gly Thr Lys Ala Ala Asn Phe Ala Val Gln Glu Cys Asp Leu Leu	
	255 260 265	
50	ATC GCC GTG GGC GCA CGT TTT GAT GAC CGG GTG ACC GGC AAA CTG AAC	2040
	Ile Ala Val Gly Ala Arg Phe Asp Asp Arg Val Thr Gly Lys Leu Asn	
	270 275 280	

55

EP 0 872 547 A1

	ACC TTC GCG CCA CAC GCC AGT GTT ATC CAT ATG GAT ATC GAC CCG GCA	2088
	Thr Phe Ala Pro His Ala Ser Val Ile His Met Asp Ile Asp Pro Ala	
5	285 290 295	
	GAA ATG AAC AAG CTG CGT CAG GCA CAT GTG GCA TTA CAA GGT GAT TTA	2136
	Glu Met Asn Lys Leu Arg Gln Ala His Val Ala Leu Gln Gly Asp Leu	
10	300 305 310	
	AAT GCT CTG TTA CCA GCA TTA CAG CAG CCG TTA AAT CAA TGT GAC TGG	2184
	Asn Ala Leu Leu Pro Ala Leu Gln Gln Pro Leu Asn Gln Cys Asp Trp	
	315 320 325 330	
15	CAG CAA CAC TGC GCG CAG CTG CGT GAT GAA CAT TCC TGG CGT TAC GAC	2232
	Gln Gln His Cys Ala Gln Leu Arg Asp Glu His Ser Trp Arg Tyr Asp	
	335 340 345	
20	CAT CCC GGT GAC GCT ATC TAC GCG CCG TTG TTG TTA AAA CAA CTG TCG	2280
	His Pro Gly Asp Ala Ile Tyr Ala Pro Leu Leu Leu Lys Gln Leu Ser	
	350 355 360	
	GAT CGT AAA CCT GCG GAT TGC GTC GTG ACC ACA GAT GTG GGG CAG CAC	2328
25	Asp Arg Lys Pro Ala Asp Cys Val Val Thr Thr Asp Val Gly Gln His	
	365 370 375	
	CAG ATG TGG GCT GCG CAG CAC ATC GCC CAC ACT CGC CCG GAA AAT TTC	2376
	Gln Met Trp Ala Ala Gln His Ile Ala His Thr Arg Pro Glu Asn Phe	
30	380 385 390	
	ATC ACC TCC AGC GGT TTA GGT ACC ATG GGT TTT GGT TTA CCG GCG GCG	2424
	Ile Thr Ser Ser Gly Leu Gly Thr Met Gly Phe Gly Leu Pro Ala Ala	
35	395 400 405 410	
	GTT GGC GCA CAA GTC GCG CGA CCG AAC GAT ACC GTT GTC TGT ATC TCC	2472
	Val Gly Ala Gln Val Ala Arg Pro Asn Asp Thr Val Val Cys Ile Ser	
	415 420 425	
40	GGT GAC GGC TCT TTC ATG ATG AAT GTG CAA GAG CTG GGC ACC GTA AAA	2520
	Gly Asp Gly Ser Phe Met Met Asn Val Gln Glu Leu Gly Thr Val Lys	
	430 435 440	
45	CGC AAG CAG TTA CCG TTG AAA ATC GTC TTA CTC GAT AAC CAA CGG TTA	2568
	Arg Lys Gln Leu Pro Leu Lys Ile Val Leu Leu Asp Asn Gln Arg Leu	
	445 450 455	
50	GGG ATG GTT CGA CAA TGG CAG CAA CTG TTT TTT CAG GAA CGA TAC AGC	2616
	Gly Met Val Arg Gln Trp Gln Gln Leu Phe Phe Gln Glu Arg Tyr Ser	
	460 465 470	

55

EP 0 872 547 A1

5 GAA ACC ACC CTT ACT GAT AAC CCC GAT TTC CTC ATG TTA GCC AGC GCC 2664
 Glu Thr Thr Leu Thr Asp Asn Pro Asp Phe Leu Met Leu Ala Ser Ala
 475 480 485 490
 TTC GGC ATC CAT GGC CAA CAC ATC ACC CGG AAA GAC CAG GTT GAA GCG 2712
 Phe Gly Ile His Gly Gln His Ile Thr Arg Lys Asp Gln Val Glu Ala
 495 500 505
 10 GCA CTC GAC ACC ATG CTG AAC AGT GAT GGG CCA TAC CTG CTT CAT GTC 2760
 Ala Leu Asp Thr Met Leu Asn Ser Asp Gly Pro Tyr Leu Leu His Val
 510 515 520
 15 TCA ATC GAC GAA CTT GAG AAC GTC TGG CCG CTG GTG CCG CCT GGC GCC 2808
 Ser Ile Asp Glu Leu Glu Asn Val Trp Pro Leu Val Pro Pro Gly Ala
 525 530 535
 20 AGT AAT TCA GAA ATG TTG GAG AAA TTA TCA TGA 2841
 Ser Asn Ser Glu Met Leu Glu Lys Leu Ser
 540 545

25 (2) INFORMATION FOR SEQ ID NO:2:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 548 amino acids
 30 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULAR TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

35 Met Asn Gly Ala Gln Trp Val Val His Ala Leu Arg Ala Gln Gly Val
 1 5 10 15
 Asn Thr Val Phe Gly Tyr Pro Gly Gly Ala Ile Met Pro Val Tyr Asp
 40 20 25 30
 Ala Leu Tyr Asp Gly Gly Val Glu His Leu Leu Cys Arg His Glu Gln
 35 40 45
 45 Gly Ala Ala Met Ala Ala Ile Gly Tyr Ala Arg Ala Thr Gly Lys Thr
 50 55 60
 Gly Val Cys Ile Ala Thr Ser Gly Pro Gly Ala Thr Asn Leu Ile Thr
 65 70 75 80
 50 Gly Leu Ala Asp Ala Leu Leu Asp Ser Ile Pro Val Val Ala Ile Thr
 85 90 95

55

EP 0 872 547 A1

Gly Gln Val Ser Ala Pro Phe Ile Gly Thr Asp Ala Phe Gln Glu Val
 100 105 110
 5 Asp Val Leu Gly Leu Ser Leu Ala Cys Thr Lys His Ser Phe Leu Val
 115 120 125
 Gln Ser Leu Glu Glu Leu Pro Arg Ile Met Ala Glu Ala Phe Asp Val
 130 135 140
 10 Ala Cys Ser Gly Arg Pro Gly Pro Val Leu Val Asp Ile Pro Lys Asp
 145 150 155 160
 Ile Gln Leu Ala Ser Gly Asp Leu Glu Pro Trp Phe Thr Thr Val Glu
 15 165 170 175
 Asn Glu Val Thr Phe Pro His Ala Glu Val Glu Gln Ala Arg Gln Met
 180 185 190
 20 Leu Ala Lys Ala Gln Lys Pro Met Leu Tyr Val Gly Gly Gly Val Gly
 195 200 205
 Met Ala Gln Ala Val Pro Ala Leu Arg Glu Phe Leu Ala Ala Thr Lys
 210 215 220
 25 Met Pro Ala Thr Cys Thr Leu Lys Gly Leu Gly Ala Val Glu Ala Asp
 225 230 235 240
 Tyr Pro Tyr Tyr Leu Gly Met Leu Gly Met His Gly Thr Lys Ala Ala
 245 250 255
 30 Asn Phe Ala Val Gln Glu Cys Asp Leu Leu Ile Ala Val Gly Ala Arg
 260 265 270
 Phe Asp Asp Arg Val Thr Gly Lys Leu Asn Thr Phe Ala Pro His Ala
 275 280 285
 35 Ser Val Ile His Met Asp Ile Asp Pro Ala Glu Met Asn Lys Leu Arg
 290 295 300
 Gln Ala His Val Ala Leu Gln Gly Asp Leu Asn Ala Leu Leu Pro Ala
 305 310 315 320
 40 Leu Gln Gln Pro Leu Asn Gln Cys Asp Trp Gln Gln His Cys Ala Gln
 325 330 335
 45 Leu Arg Asp Glu His Ser Trp Arg Tyr Asp His Pro Gly Asp Ala Ile
 340 345 350
 Tyr Ala Pro Leu Leu Leu Lys Gln Leu Ser Asp Arg Lys Pro Ala Asp
 355 360 365
 50 Cys Val Val Thr Thr Asp Val Gly Gln His Gln Met Trp Ala Ala Gln
 370 375 380
 55

His Ile Ala His Thr Arg Pro Glu Asn Phe Ile Thr Ser Ser Gly Leu
 385 390 395 400
 Gly Thr Met Gly Phe Gly Leu Pro Ala Ala Val Gly Ala Gln Val Ala
 405 410 415
 Arg Pro Asn Asp Thr Val Val Cys Ile Ser Gly Asp Gly Ser Phe Met
 420 425 430
 Met Asn Val Gln Glu Leu Gly Thr Val Lys Arg Lys Gln Leu Pro Leu
 435 440 445
 Lys Ile Val Leu Leu Asp Asn Gln Arg Leu Gly Met Val Arg Gln Trp
 450 455 460
 Gln Gln Leu Phe Phe Gln Glu Arg Tyr Ser Glu Thr Thr Leu Thr Asp
 465 470 475 480
 Asn Pro Asp Phe Leu Met Leu Ala Ser Ala Phe Gly Ile His Gly Gln
 485 490 495
 His Ile Thr Arg Lys Asp Gln Val Glu Ala Ala Leu Asp Thr Met Leu
 500 505 510
 Asn Ser Asp Gly Pro Tyr Leu Leu His Val Ser Ile Asp Glu Leu Glu
 515 520 525
 Asn Val Trp Pro Leu Val Pro Pro Gly Ala Ser Asn Ser Glu Met Leu
 530 535 540
 Glu Lys Leu Ser
 545

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: other nucleic acid

(A) DESCRIPTION: /desc="synthetic DNA"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TAACATCACT GAGATCATGT TG

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: other nucleic acid

- (A) DESCRIPTION: /desc="synthetic DNA"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCTTTTCTTG CATCTTGTC G

21

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: other nucleic acid

- (A) DESCRIPTION: /desc="synthetic DNA"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCTGTTTCTC AAGATTCAGG AC

22

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: other nucleic acid

- (A) DESCRIPTION: /desc="synthetic DNA"

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
CGCCGGTAAA CCAAAACCC

19

10 Claims

1. A microorganism belonging to the genus Escherichia and having a capability of producing L-valine or L-leucine, which requires lipoic acid for growth.
- 15 2. A microorganism belonging to the genus Escherichia and having a capability of producing L-valine or L-leucine, which is deficient in H⁺-ATPase activity.
3. A microorganism belonging to the genus Escherichia and having a capability of producing L-valine or L-leucine, which requires lipoic acid for growth and which is deficient in H⁺-ATPase activity.
- 20 4. A microorganism according to any one of claims 1 to 3, which has the capability of producing L-valine by carrying a gene for L-valine biosynthesis, of which regulatory mechanism is substantially released.
5. A microorganism according to any one of claims 1 to 3, which has the capability of producing L-leucine by carrying a gene for L-leucine biosynthesis, of which regulatory mechanism is substantially released.
- 25 6. A microorganism according to claim 4, which has the capability of producing L-valine by introducing a DNA fragment including an ilvGMEDA operon which express each of ilvG, ilvM, ilvE and ilvD genes, and does not express threonine deaminase, into a cell.
- 30 7. A microorganism according to claim 6 wherein a region of the ilvGMEDA operon necessary for attenuation by L-valine and/or L-isoleucine and/or L-leucine is deleted.
8. A microorganism according to claim 7 wherein the region necessary for the attenuation which is deleted has nucleotides 953 to 1160 of a sequence shown in SEQ ID NO: 1.
- 35 9. A microorganism according to any one of claims 1 to 8, which is Escherichia coli.
10. A microorganism according to claim 9, which is Escherichia coli W1485atpA401/pMWdAR6, W1485lip2/pMWdAR6 or AJ12631/pMWdAR6.
- 40 11. A method for producing L-valine which comprises culturing the microorganism having the capability of producing L-valine as defined in any one of claims 1 to 4 and 6 to 9 in a liquid medium to allow L-valine to be produced and accumulated in the medium, and collecting it.
- 45 12. A method for producing L-leucine which comprises culturing the microorganism having the capability of producing L-leucine as defined in any one of claims 1 to 3, 5 and 9 in a liquid medium to allow L-leucine to be produced and accumulated in the medium, and collecting it.

50

55

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP95/01719

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl⁶ C12N1/21, C12N1/20, C12P13/08, C12P13/06// (C12N1/21, C12R1:19), (C12P13/08, C12P1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl⁶ C12N1/00-3/00, C12P13/00-13/24

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS PREVIEWS, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, 5-137568, A (Ajinomoto Co., Inc.), June 1, 1993 (01. 06. 93) (Family: none)	1 - 3
A		4 - 12
X	HERBERT A A et al. "Lipoic-acid Content of Escherichia-coli and Other Microorganisms", Arch. Microbiol., (1975 (RECD.1976) Vol. 106, No. 3, p. 259-266	1, 3
A		2, 4-12
P, X	YOKOTA A, et al. "Pyruvic acid production by an F-1-ATPase-defective mutant of Escherichia coli W1485lip2", Bioscience Biotechnology and Biochemistry, (1994. Dec) Vol. 58, No. 12, p. 2164-2167	1, 3
P, A		2, 4-12
P, X	YOKOTA A, et al. "Pyruvic acid production by a lipoic acid auxotroph of Escherichia coli W1485", Applied Microbiol. Biotech., (1994) Vol. 41, No. 6, p. 638-643	1, 3

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

November 21, 1995 (21. 11. 95)

Date of mailing of the international search report

December 19, 1995 (19. 12. 95)

Name and mailing address of the ISA/

Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP95/01719

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A		2, 4-12
A	Hiroshi Aida and four others "Amino Acid Fermentation" May 30, 1986 (30. 05. 86) Gakkai Shuppan Center, p. 397-422	1 - 12
A	JP, 4-330275, A (Ajinomoto Co., Inc.), November 18, 1992 (18. 11. 92) (Family: none)	1 - 12
A	JP, 61-185195, A (Mitsui Toatsu Chemicals, Inc.), August 18, 1986 (18. 08. 86) (Family: none)	1 - 12
A	EP, 519113, A1 (Ajinomoto K.K.), December 23, 1992 (23. 12. 92) (Family: none)	1 - 12
A	WO, 8702984, A (Amer. Biogenetics Co.), May 21, 1987 (21. 05. 87) & AU, 8767372, A & EP, 245497, A & JP, 63501687, W	1 - 12

Form PCT/ISA/210 (continuation of second sheet) (July 1992)